Small Molecules

17 Mar 2007 Exelixis Files IND Application for XL147
17 Mar 2007 Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)
17 Mar 2007 Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
17 Mar 2007 Nippon Shinyaku and Teva terminate HMN-214 License Agreement
16 Mar 2007 Trimeris and Roche Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors
16 Mar 2007 Acura Pharmaceuticals, Inc. Updates OxyADF Tablets Development Program and Results of Study AP-ADF-102
16 Mar 2007 Eli Lilly Withdraws Its Marketing Authorization Application for Arxxant
15 Mar 2007 Avigen Receives Approval to Initiate AV650 Phase II Clinical Development
15 Mar 2007 Optimer Pharmaceuticals Advances Difimicin into Phase 3 Clinical Trial
15 Mar 2007 Curis Selects First Development Candidate from its Targeted Cancer Drug Development Platform
15 Mar 2007 Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study
14 Mar 2007 Tyrima(TM) Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties
14 Mar 2007 FDA approves Tykerb(R) (lapatinib) in combination with Xeloda(R) (capecitabine) for the treatment of advanced or metastatic breast cancer in women who have progressed on prior therapy
14 Mar 2007 Spectrum Pharmaceuticals Reaches Special Protocol Assessment Agreement With FDA on Phase 3 Trials for EOquin(R)
14 Mar 2007 Active Biotech's I-3D micro-dosing clinical trial concluded
14 Mar 2007 Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG-irinotecan) for Potential to Treat Patients with Refractory Solid Tumors
14 Mar 2007 Cellzome Receives First Milestone Payment for Alzheimer's Program From Ortho-McNeil Pharmaceutical, Inc
14 Mar 2007 Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement
14 Mar 2007 Xytis Enrolls First Patient in Phase II Clinical Study With Anatibant (XY2405) for Traumatic Brain Injury
14 Mar 2007 Obecure Initiates Phase II Weight Gain Prevention Study for Patients Taking Zyprexa
14 Mar 2007 Memory Pharmaceuticals Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease
13 Mar 2007 TorreyPines Therapeutics Initiates Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
13 Mar 2007 Panacos Announces Bevirimat Phase 2b Dose Escalation Strategy
13 Mar 2007 Depomed Files Investigational New Drug Application For Gabapentin Gr For The Treatment Of Postmenopausal Hot Flashes
13 Mar 2007 New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up